Search
Spotlight
A Review of Data from the Vargas Trujillo et al Study on Individualizing Treatment Decisions in Girls With CPP
Diabetes Dialogue
Essential Resources for the Treatment of Central Precocious Puberty
Essential Resources for the Treatment of Diabetes with CGM
The Role of CGM in Diabetes Management Video
A Review of Data from the Vargas Trujillo et al Study on Individualizing Treatment Decisions in Girls With CPP
Diabetes Dialogue
Essential Resources for the Treatment of Central Precocious Puberty
Essential Resources for the Treatment of Diabetes with CGM
The Role of CGM in Diabetes Management Video
Clinical
View More
Cardiology
Cushing's Disease
Diabetes
Endocrine Diseases
Men's Health
Nutrition
Osteoporosis
Pediatrics
Thyroid Disorders
Weight Management
Women's Health
Cardiology
Cushing's Disease
Diabetes
Endocrine Diseases
Men's Health
Nutrition
Osteoporosis
Pediatrics
Thyroid Disorders
Weight Management
Women's Health
News
Media
AROUND THE PRACTICE
Between The Lines
EndoView
Expert Interviews
Medical World News
Podcasts
Provider Toolkits
AROUND THE PRACTICE
Between The Lines
EndoView
Expert Interviews
Medical World News
Podcasts
Provider Toolkits
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Columns
Resources
CME/CE
Clinical Guidelines
Image IQ
Partners
Webinars
CME/CE
Clinical Guidelines
Image IQ
Partners
Webinars
Subscribe
Search
Spotlight
A Review of Data from the Vargas Trujillo et al Study on Individualizing Treatment Decisions in Girls With CPP
Diabetes Dialogue
Essential Resources for the Treatment of Central Precocious Puberty
Essential Resources for the Treatment of Diabetes with CGM
The Role of CGM in Diabetes Management Video
Clinical
See All >
Cardiology
Cushing's Disease
Diabetes
Endocrine Diseases
Men's Health
Nutrition
Osteoporosis
Pediatrics
Thyroid Disorders
Weight Management
Women's Health
SGLT2 + GLP-1 =
May 19, 2015
Payal Kohli, MD
Combination therapy with an SGLT2 inhibitor and GLP-1 receptor agonist:
A. Is safe and well tolerated
B. Achieves double the weight loss of a SGLT2 inhibitor alone
C. Is additive with respect to its effects on weight loss.
D. All of the above
E. None of the above
Vote